Cytokinetics price target raised to $99 from $95 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Cytokinetics (CYTK) to $99 from $95 and keeps a Buy rating on the shares. Cytokinetics received FDA approval for aficamten, now branded Myqorzo, to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, improving functional capacity and symptoms, the analyst tells investors in a research note. The label appears marginally superior to Bristol Myers’ (BMY) Camzyos and aligns with expectations for an incrementally differentiated REMS program, the firm says.